EYLEA
As listed in the register: EYLEA 114,3 mg/mL, solution injectable en seringue préremplie
114,3 mg · solution injectable
- Prescription only
- Active substance
- Aflibercept
- Made by
- BAYER AG (ALLEMAGNE)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (EYLEA). It describes the substance, not this exact product.
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells.
VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-07
Safety of the active substance
From the US prescribing label for the same active substance (EYLEA). It describes the substance, not this exact product.
- Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
Details
| Made by | BAYER AG (ALLEMAGNE) |
|---|---|
| Active substance | Aflibercept |
| Strength | 114,3 mg |
| Form | solution injectable |
| Route | intravitréenne |
| Dispensing (as stated by the register) | prescription réservée aux spécialistes et services OPHTALMOLOGIE · liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/12/797 |
| Name in the register | EYLEA 114,3 mg/mL, solution injectable en seringue préremplie |
| Packs | 1 seringue(s) préremplie(s) en verre de 0,184 ml |
| CIS | 67140625 |
| CIP13 | 3400930303122 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution injectable4 products
40 mg2
40 mg · 2 companies
114,3 mg2
114,3 mg · 2 companies
- BAYER AG (ALLEMAGNE) · this page
- BAYER AG (ALLEMAGNE)
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.